Best Practice & Research Clinical Haematology最新文献

筛选
英文 中文
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML 我们如何干预以减轻AML移植后复发?减轻AML移植后复发的策略
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101411
Jonathan A. Gutman
{"title":"How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML","authors":"Jonathan A. Gutman","doi":"10.1016/j.beha.2022.101411","DOIUrl":"10.1016/j.beha.2022.101411","url":null,"abstract":"<div><p>Although allogeneic hematopoietic stem cell transplantation<span> (allo-HSCT) is a curative approach for patients with acute myeloid leukemia<span> (AML), relapse is a common occurrence. Several strategies, such as choice of conditioning regimen, donor lymphocyte infusions, pharmacologic agents, and cellular therapy approaches, are currently being developed to improve transplantation outcomes. This review outlines some important interventions and considerations to lower the burden of post-transplantation relapse in AML.</span></span></p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10473777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How can we incorporate molecular data into the IPSS? 我们如何将分子数据整合到IPSS中?
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101410
Rafael Bejar
{"title":"How can we incorporate molecular data into the IPSS?","authors":"Rafael Bejar","doi":"10.1016/j.beha.2022.101410","DOIUrl":"10.1016/j.beha.2022.101410","url":null,"abstract":"","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692622000652/pdfft?md5=0cace80c68e2060bb5aaed2bd9effdf7&pid=1-s2.0-S1521692622000652-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10473778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consolidation chemotherapy in AML: Are we playing with a full deck of cards? AML的巩固化疗:我们是否在玩全套纸牌?
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101408
Richard M. Stone
{"title":"Consolidation chemotherapy in AML: Are we playing with a full deck of cards?","authors":"Richard M. Stone","doi":"10.1016/j.beha.2022.101408","DOIUrl":"10.1016/j.beha.2022.101408","url":null,"abstract":"<div><p><span><span><span>The safe diminution of leukemic cell numbers to a level such that the patient will not succumb to their disease has been an achievable, yet often elusive goal in AML. Disease heterogeneity based both on biological features as well as on </span>patient characteristics such as age, exposure to prior to anti-cancer chemotherapy and co-morbidities play a role in an allowing the physician to predict which patient has a greater or lesser chance to be cured after a diagnosis of </span>acute myeloid leukemia<span><span>. Cure rates range from 95% in younger patients with non-high-risk acute promyelocytic leukemia to essentially zero in older adults with intrinsically resistant biologies such as complex </span>karyotype and/or </span></span><em>TP53</em><span><span> mutations. One unifying feature of all AMLs, however, is the notion that whatever initial therapy is used, while possible to eradicate all morphological evidence of disease in a sizeable fraction of patients, an initial cycle (or two) is not sufficient to yield a low enough disease burden<span> to prevent eventual relapse. Thus, the application of additional chemotherapy after the initial complete remission is received (post-remission therapy generally or consolidation therapy if a myelointense approach is used) is absolutely required for the patient to have a reasonable chance at cure. The widely accepted principle of the need to provide post-remission therapy leads to multiple controversies pertaining to the appropriate intensity, drug choice, and duration of exposure to consolidation chemotherapy, which can range from repetitive cycles of non-intensive therapy, up to and including a myeloblative allogeneic </span></span>stem cell transplant. In this review, both the principles and the individual strategies that can be used once remission is achieved, will be examined.</span></p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10473779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How can we design a better care model to address the acute distress of an acute leukemia diagnosis? Care models to address the acute distress of an acute leukemia diagnosis 我们如何设计一个更好的护理模式来解决急性白血病诊断的急性痛苦?护理模式,以解决急性白血病诊断的急性痛苦
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101409
Areej El-Jawahri
{"title":"How can we design a better care model to address the acute distress of an acute leukemia diagnosis? Care models to address the acute distress of an acute leukemia diagnosis","authors":"Areej El-Jawahri","doi":"10.1016/j.beha.2022.101409","DOIUrl":"10.1016/j.beha.2022.101409","url":null,"abstract":"","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10762652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent progress in acute leukemia and myelodysplasia 急性白血病和骨髓异常增生的最新进展
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101415
Hetty E. Carraway , Daniel A. Pollyea , Eytan M. Stein
{"title":"Recent progress in acute leukemia and myelodysplasia","authors":"Hetty E. Carraway ,&nbsp;Daniel A. Pollyea ,&nbsp;Eytan M. Stein","doi":"10.1016/j.beha.2022.101415","DOIUrl":"10.1016/j.beha.2022.101415","url":null,"abstract":"<div><p>The advances and progress in the understanding and management of acute leukemia and myelodysplasia continue to occur at an exponential rate. While this has led to more therapy options, clinicians and researchers are now facing more challenges in terms of clinical decision-making and more unanswered questions. This paper has outlined some conundrums in acute leukemia and myelodysplasia, and the efforts that are underway to address these.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10473775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms 我们如何改进MDS的疗效评估?改善MDS治疗模式疗效评估的策略
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101405
Rafael Bejar
{"title":"How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms","authors":"Rafael Bejar","doi":"10.1016/j.beha.2022.101405","DOIUrl":"10.1016/j.beha.2022.101405","url":null,"abstract":"<div><p>Evaluating response to treatment in MDS represents a major challenge due to its associated complexity and heterogeneity. Although response criteria have been proposed by the IWG and revised on several occasions, these criteria have limitations. This review has outlined some refinements that can be used to improve response assessment and to ensure the identification of clinically meaningful endpoints.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692622000603/pdfft?md5=9bc84f65f51306c6fdf8d51271a2e202&pid=1-s2.0-S1521692622000603-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10762651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
COVID-19 and antiphospholipid antibodies COVID-19和抗磷脂抗体
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-09-01 DOI: 10.1016/j.beha.2022.101402
Ayesha Butt , Doruk Erkan , Alfred Ian Lee
{"title":"COVID-19 and antiphospholipid antibodies","authors":"Ayesha Butt ,&nbsp;Doruk Erkan ,&nbsp;Alfred Ian Lee","doi":"10.1016/j.beha.2022.101402","DOIUrl":"10.1016/j.beha.2022.101402","url":null,"abstract":"<div><p>Antiphospholipid syndrome and the coagulopathy of COVID-19 share many pathophysiologic features, including endotheliopathy, hypercoagulability, and activation of platelets, complement pathways, and neutrophil extracellular traps, all acting in concert via a model of immunothrombosis. Antiphospholipid antibody production in COVID-19 is common, with 50% of COVID-19 patients being positive for lupus anticoagulant in some studies, and with non-Sapporo criteria antiphospholipid antibodies being prevalent as well. The biological significance of antiphospholipid antibodies in COVID-19 is uncertain, as such antibodies are usually transient, and studies examining clinical outcomes in COVID-19 patients with and without antiphospholipid antibodies have yielded conflicting results. In this review, we explore the biology of antiphospholipid antibodies in COVID-19 and other infections and discuss mechanisms of thrombogenesis in antiphospholipid syndrome and parallels with COVID-19 coagulopathy. In addition, we review the existing literature on safety of COVID-19 vaccination in patients with antiphospholipid antibodies and antiphospholipid syndrome.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9549699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Coagulopathy in COVID-19 and anticoagulation clinical trials COVID-19的凝血功能障碍和抗凝临床试验
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-09-01 DOI: 10.1016/j.beha.2022.101377
Heng Zhang , Qifang Lao , Jue Zhang , Jieqing Zhu
{"title":"Coagulopathy in COVID-19 and anticoagulation clinical trials","authors":"Heng Zhang ,&nbsp;Qifang Lao ,&nbsp;Jue Zhang ,&nbsp;Jieqing Zhu","doi":"10.1016/j.beha.2022.101377","DOIUrl":"10.1016/j.beha.2022.101377","url":null,"abstract":"<div><p>Severe acute respiratory disease coronavirus 2 (SARS-COV-2) first emerged in Wuhan, China, in December 2019 and has caused a global pandemic of a scale unprecedented in the modern era. People infected with SARS-CoV-2 can be asymptomatic, moderate symptomatic or develop severe COVID-19. Other than the typical acute respiratory distress syndrome (ARDS), patients with moderate or severe COVID-19 also develop a distinctive systemic coagulopathy, known as COVID-19-associated coagulopathy (CAC), which is different from sepsis-related forms of disseminated intravascular coagulation (DIC). Endotheliopathy or endotheliitis are other unique features of CAC. The endothelial cell perturbation can further increase the risk of thrombotic events in COVID-19 patients. In this review, we will summarize the current knowledge on COVID-19 coagulopathy and the possible mechanisms for the condition. We also discuss the results of clinical trials testing methods for mitigating thrombosis events in COVID-19 patients.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9800898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Dysregulation of Protein S in COVID-19 蛋白S在COVID-19中的失调
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-09-01 DOI: 10.1016/j.beha.2022.101376
Martha M.S. Sim , Jeremy P. Wood
{"title":"Dysregulation of Protein S in COVID-19","authors":"Martha M.S. Sim ,&nbsp;Jeremy P. Wood","doi":"10.1016/j.beha.2022.101376","DOIUrl":"10.1016/j.beha.2022.101376","url":null,"abstract":"<div><p>Coronavirus Disease 2019 (COVID-19) has been widely associated with increased thrombotic risk, with many different proposed mechanisms. One such mechanism is acquired deficiency of protein S (PS), a plasma protein that regulates coagulation and inflammatory processes, including complement activation and efferocytosis. Acquired PS deficiency is common in patients with severe viral infections and has been reported in multiple studies of COVID-19. This deficiency may be caused by consumption, degradation, or clearance of the protein, by decreased synthesis, or by binding of PS to other plasma proteins, which block its anticoagulant activity. Here, we review the functions of PS, the evidence of acquired PS deficiency in COVID-19 patients, the potential mechanisms of PS deficiency, and the evidence that those mechanisms may be occurring in COVID-19.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9578815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Editorial Board / Aims & Scope 编辑委员会/目标与范围
IF 2.1 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2022-09-01 DOI: 10.1016/S1521-6926(22)00075-5
{"title":"Editorial Board / Aims & Scope","authors":"","doi":"10.1016/S1521-6926(22)00075-5","DOIUrl":"https://doi.org/10.1016/S1521-6926(22)00075-5","url":null,"abstract":"","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692622000755/pdfft?md5=eac0b05f49880e4c96d6fb7c848b4120&pid=1-s2.0-S1521692622000755-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138323708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信